| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 103,352 | 216,893 | ||
| Investments in marketable securities | 88,311 | 20,744 | ||
| Trade receivables, net | 9,245 | 5,109 | ||
| Tsa receivables, net | 241,251 | 114,530 | ||
| Inventory | 2,048 | 4,513 | ||
| Prepaid manufacturing | 8,048 | 6,700 | ||
| Other prepaids and current assets | 8,700 | 11,716 | ||
| Total current assets | 460,955 | 380,205 | ||
| Property and equipment, net | 1,633 | 1,907 | ||
| Intangible assets, net | 49,484 | 52,312 | ||
| Other assets, non-current | 4,447 | 5,040 | ||
| Total assets | 516,519 | 439,464 | ||
| Accounts payable | 24,893 | 37,622 | ||
| Accrued rebates, fees and reserves | 67,010 | 96,814 | ||
| Tsa payables and accrued liabilities | 253,908 | 103,999 | ||
| Accrued compensation | 13,385 | 11,015 | ||
| Accrued and other current liabilities | 13,101 | 14,179 | ||
| Total current liabilities | 372,297 | 263,629 | ||
| Term loan, non-current | 36,957 | 36,867 | ||
| Lease liabilities, non-current | 1,946 | 2,406 | ||
| Other liabilities, non-current | 17,545 | 16,735 | ||
| Total liabilities | 428,745 | 319,637 | ||
| Common stock (0.0001 par value shares authorized 300,000,000 shares issued and outstanding 116,236,018 and 115,614,548 at september 30, 2025 and december 31, 2024, respectively) | 12 | 12 | ||
| Additional paid-in capital | 1,433,291 | 1,429,885 | ||
| Accumulated other comprehensive loss | -203 | -275 | ||
| Accumulated deficit | -1,345,326 | -1,309,795 | ||
| Total stockholders' equity (deficit) | 87,774 | 119,827 | ||
| Total liabilities and stockholders' equity (deficit) | 516,519 | 439,464 | ||
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)